Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

Major Program
Cancer Prevention Clinical Trials Network
Research Group
Gastrointestinal and Other Cancers
National Cancer Institute (NCI)
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04767984
This phase II trial studies the effect of atorvastatin in treating patients with ulcerative
colitis who have a dominant-negative missense P53 mutation and are at risk of developing
large intestinal cancer. Patients with ulcerative colitis are known to have an increased risk
of developing large intestinal cancer. Better ways to control ulcerative colitis and more
knowledge about how to prevent colon cancer are needed. Atorvastatin is a drug used to lower
the amount of cholesterol in the blood and to prevent stroke, heart attack, and angina (chest
pain). It blocks an enzyme that helps make cholesterol in the body. It also causes an
increase in the breakdown of cholesterol. The information gained from this study may help
doctors learn more about atorvastatin as an agent in cancer prevention, and may help to
improve public health.
Atorvastatin Calcium, Biospecimen Collection, Placebo Administration, Biopsy of Colon, Questionnaire Administration
Colorectal Carcinoma, Ulcerative Colitis
Seema Khan, Guang-Yu Yang, Nancy Gupta, Joel Pekow

See list of participating sites